Related Experiment Video
Updated: Nov 4, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence
Teng Ma1, Yang Su1, Jing Song2
1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Insights
Heart failure with mid-range ejection fraction (HFmrEF) is a distinct heart failure type. Patients with HFmrEF may benefit more from heart failure with reduced ejection fraction therapies.
Area of Science:
- Cardiology
- Heart Failure Research
Background:
- Heart failure (HF) poses a significant public health challenge.
- Left ventricular ejection fraction (LVEF) is key for HF assessment.
- The European Society of Cardiology defined HF with mid-range ejection fraction (HFmrEF) in 2016, a distinct phenotype between HFpEF and HFrEF.
Purpose of the Study:
- To review current knowledge on HFmrEF treatment.
- To discuss future directions for defining this unique HF phenotype.
Main Methods:
- Literature review of studies on HFmrEF.
- Analysis of treatment benefits in HFmrEF patients.
Main Results:
- HFmrEF patients may respond better to therapies typically used for HFrEF compared to HFpEF.
- This phenotype represents a potential transitional state between HFpEF and HFrEF.
Conclusions:
- Further research is needed to fully characterize HFmrEF.
- Optimizing treatment strategies for HFmrEF requires a better understanding of its specific mechanisms and patient population.
Abstract:
Heart failure (HF) is a complex syndrome causing heavy burden in public health, and the modern objective assessment of it is based on the left ventricular ejection fraction (LVEF). In 2016, the European Society of Cardiology classified the "gray area" in HF with LVEF of 40-49% as a new HF phenotype (HFmrEF) in an attempt to uncover the specific characteristics and treatment of these patients, which might recover or worsen to HFpEF or HFrEF, respectively, or conversely from these two subtypes. Up to now, many studies have demonstrated that patients with HFmrEF would possibly gain more benefits from some targeted therapies with HFrEF than those with HFpEF. This review summarizes what is known about the findings in the treatment of HFmrEF and discusses what should be done to better define the peculiar HF phenotype in the future.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Heart Failure VII: Nursing Interventions